Return to study ST000241 main page
MB Sample ID: SA011145
| Local Sample ID: | CKC2 |
| Subject ID: | SU000261 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Cell Biosource Or Supplier: | ATCC |
| Cell Strain Details: | HepG2 |
| Subject Comments: | NA |
| Cell Primary Immortalized: | Immortalized |
| Cell Passage Number: | NA |
| Cell Counts: | NA |
| Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000272 |
| Treatment Summary: | Cells treated 24hr with 500 µM Fa, analogue or BSA control. Harvested and lipids extracted and then resolved using Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS) s |
| Treatment Protocol ID: | CBC_treatment |
| Treatment Protocol Filename: | See_Comments |
| Treatment Protocol Comments: | Human hepatoma HepG2 cells (American Type Culture Collection; HB-8065) were grown in 75 ml tissue cell culture flasks in Eagle's minimal essential medium (EMEM) augmented with 10% fetal bovine serum at 37°C in a humidified atmosphere with 5% CO2. For treatment with fatty acids or analogues, the cells were seeded at a density of 2 × 106 cells in a T25-cm2 flask for 24 h. Each FA or analogue was added to the culture medium as a fatty acid-bovine serum albumin (BSA) complex (2.5:1, FA:BSA) to give 500µM final concentration. The controls in these experiments were HepG2 cells with BSA alone. After 24 h treatment, the media was collected, cells were rinsed twice with PBS and cells were harvested for complex lipid analysis. |
| Treatment Compound: | Fatty acid/BSA |
| Treatment Dose: | 500 µM (fatty acid) |
| Treatment Doseduration: | 24 hr |
| Treatment Vehicle: | PBS |
| Cell Growth Container: | 75 ml tissue cell culture flasks |
| Cell Media: | Eagle's minimal essential medium (EMEM) augmented with 10% fetal bovine serum |
| Cell Envir Cond: | 37°C in a humidified atmosphere with 5% CO2 |
| Cell Harvesting: | Typsinize and scrape |
| Cell Media Lastchanged: | 24 hr |
